Project cooperationUpdated on 27 January 2026
Improvement of quality of life in elderly patients with diffuse large B-cell lymphoma
Professor at Lund University
Lund, Sweden
About
POLAR BEAR is a randomized phase 3 trial of 300 patients comparing R-mini-CHOP and pola-R-mini CHP in patients with aggressive B-cell lymphoma >80 years, or frail 75-80 years. HRQOL is evaluated by EORTC-QLQ-C30 at baseline and during the trial.
Topic
- HORIZON-MISS-2026-02-CANCER-07: Improve the Quality of Life of older cancer patients
Type
- Consortium/Coordinator seeks Partners
Attached files
Organisation
Similar opportunities
Project cooperation
Facilitating contacts with cancer researchers at Medical University of Vienna
- Completing the consortia
- HORIZON-MISS-2026-02-CANCER-04: Earlier and more precise palliative care
- HORIZON-MISS-2026-02-CANCER-01: Virtual Human Twin (VHT) Models for Cancer Research
- HORIZON-MISS-2026-02-CANCER-07: Improve the Quality of Life of older cancer patients
- HORIZON-MISS-2026-02-CANCER-02: Microbiome for early cancer prediction before the onset of disease
- HORIZON-MISS-2026-02-CANCER-03: Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers
Reinhard Eckert
Research Service at Medical University of Vienna
Vienna, Austria
Project cooperation
- Offering Expertise to Consortias
- Design - setting the project scope
- Consortium/Coordinator seeks Partners
- Ideation - identifying the project idea
- HORIZON-MISS-2026-02-CANCER-04: Earlier and more precise palliative care
- HORIZON-MISS-2026-02-CANCER-07: Improve the Quality of Life of older cancer patients
- HORIZON-MISS-2026-02-CANCER-05: Boosting mental health of young cancer survivors through the European Cancer Patient Digital Centre (ECPDC)
Paolo Pacciolla
Freelancer at Muni Sangha
Pavia, Italy
Project cooperation
- Offering Expertise to Consortias
- HORIZON-MISS-2026-02-CANCER-07: Improve the Quality of Life of older cancer patients
- HORIZON-MISS-2026-02-CANCER-03: Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers
Javier Carmona
Head of Scientific Strategy at Vall d'Hebron Institute of Oncology
BARCELONA, Spain